Somaxon PHARMACEUTICAL

Somaxon Pharmaceuticals, Inc.
Investor Relations Department
10935 Vista Sorrento Parkway,
Suite 250
San Diego, CA 92130
United States

Visit IR website
Sign-up for email alerts

NASDAQ: SOMX [1]		
Last Trade:		3.00
Trade Time:		3:59 PM ET Mar 6, 2013
Change:	0.10	(3.448%)
Day Range		2.91 - 3.00
52-Week Range		1.29 - 5.44
Volume		21,800
Market Cap. ($M)		21.612
Shares Out (M)		7.204

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon's lead product candidate is Silenor® (doxepin) for the treatment of insomnia.... (more)

Stock Performance

Press Releases [View all]

Mar 6, 2013
Pernix Therapeutics Completes Acquisition of Somaxon Pharmaceuticals, Inc.

Feb 5, 2013
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Actavis

Dec 17, 2012
Somaxon Announces That Paladin Labs Has Received Approval of New Drug Submission for Silenor (R) in Canada

Dec 11, 2012
Pernix Therapeutics Announces Agreement to Acquire Somaxon Pharmaceuticals, Inc.

Oct 31, 2012
Somaxon Pharmaceuticals Reports Third Quarter 2012 Financial Results

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

Aug 27, 2012
Definitive Proxy Statement

Nov 1, 2012
Quarterly Report (10-Q)

Aug 8, 2012
Quarterly Report (10-Q)

May 10, 2012
Quarterly Report (10-Q)

NASDAQ OMX